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Cancer is the worldwide leading cause of death and
inspires extensive research on its prevention, early diag-
nosis, and treatment. While cell proliferation is impor-
tant for the regeneration of damaged tissue, apoptosis
is crucial for the maintenance of tissue homeostasis.
An imbalance between these 2 components can lead
to the development of cancer.
Molecular Pathways of Apoptosis
Underlying Cancer Development
Apoptosis is initiated via the mitochondrial or the death
receptor pathway. Central to the mitochondrial pathway
is the release of cytochrome c from the mitochondria,
leading to activation of the caspase cascade and execu-
tion of apoptosis.1 The mitochondrial pathway is regu-
lated by the BCL-2 family of proteins, i.e. proapoptotic
BAX and BAK as well as antiapoptotic BCL-2 and
BCL-xL. The death receptor pathway is activated when
the cell surface death receptor—Fas—is bound by its
ligand—Fas ligand, resulting in recruitment of the
adaptor protein FADD and procaspase 8 to the intra-
cellular domain of the death receptor and subsequent
caspase activation. Inhibitors of apoptosis have been
shown to play a role in oncogenesis through direct
caspase and procaspase inhibition (primarily caspases 3
and 7) and transcription factor NF-κB signaling.2 In
addition, some proapoptotic molecules are downre-
gulated or inactivated in cancer cells, such as Fas, p53,
Bax or Bid.3
Deregulated Apoptosis in Female 
Genital Tract Cancer
Several lines of evidence showing deregulated apoptosis
in female genital tract cancer have been reported. Ge-
netic polymorphisms of p53 and p21, a downstream
mediator of p53, have been found to be associated with
the development of endometrial cancer.4 Statistically
significant higher nuclear p53 levels were found in
malignant compared to normal human endometrial
specimens by the Western blot technique.5 Higher
expression of BAG-1, an antiapoptotic molecule that
binds BCL-2, was also found in high-grade endometrial
cancer compared with normal endometrium.6 More-
over, the BAX gene frameshift mutation was frequently
detected in endometrial carcinoma, leading to a loss
of BAX expression and resistance to apoptosis.7 In
primary Fallopian tube carcinoma, a high incidence of
p53, HER-2/neu and c-myc overexpression was also
found.8 In cases of cervical squamous cell carcinoma
treated with radiotherapy, BAX expression was associ-
ated with good survival while BCL-2 expression was
associated with poor survival.9 There have been limited
reports on apoptosis marker analysis of female genital
tract sarcoma because of the low incidence. Uterine
leiomyosarcoma has been found to be associated with
a higher positive rate of p21, p53, and BAX compared
with uterine leiomyoma, and BCL-2-positive leiomyo-
sarcoma was shown to be associated with a longer
time to recurrence.10 In a case of sarcoma botryoides
of the uterine cervix, a point mutation of the p53
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gene was found, with overexpression of p53 protein in
more than half of the neoplastic cells.11 Liu et al showed
that p53, BCL-2, BAX, and c-myc were frequently
expressed in female genital tract sarcomas.12 A signifi-
cant positive association was detected between BAX and
c-myc. In both univariate and multivariate analyses,
they found that overexpression of p53 was associated
with poorer survival.
Roles of p53 in Pathogenesis and
Prognosis of Cancer
Somatic p53 mutations are found in approximately
50% of human cancers, but in the remaining wild-type
p53-carrying tumors, the p53 pathway may also be
inactivated via indirect mechanisms, such as interaction
with the human murine double minute 2 (MDM2)
oncoprotein, that lead to p53 destabilization.13 In
female genital tract sarcomas, Liu et al found that 44%
of the 54 cases were positive for p53.12 In response to
cellular exposure to exogenous or endogenous car-
cinogens, the p53 proteins, as transcription factors,
integrate multiple cellular stress signals to trigger tran-
scription of genes involved in either cell cycle arrest or
apoptosis. In addition, p53 also interacts with BCL-xL
to induce transcription-independent apoptosis. The
p53 family also includes p63 and p73, and intimate
interactions exist among these 3 proteins. While p63
is essential for proliferation and differentiation, p73
promotes apoptosis in response to DNA damage. Some
mutant p53 proteins, but not wild-type p53 proteins,
bind to p73 to inhibit its apoptotic activity, which
may be one of the causes of poor prognosis in cancer
patients with p53 mutation. In these p53-positive
cancer patients, the tumors may have a poor response
to chemotherapeutic agents due to the aforementioned
inhibitory effects of mutant p53 on apoptosis. In fact,
p53 alone or in combination with other factors, such
as hypoxia-inducible factor 1α and BCL-2, significantly
predicts poor prognosis in many types of cancer. In the
study on female genital tract sarcomas presented by
Liu et al, 5-year survival was shown to drop from 55%
in patients with p53-negative tumors to 30% in patients
with p53-positive tumors.12
Therapeutic Implications of Apoptosis-
related Markers
Since p53 is either mutated or inactivated in almost all
cancer cells, restoration of p53 to inhibit tumor growth
is a promising cancer therapy strategy. Molecules have
been developed to either restore wild-type conformation
to mutant p53 or induce mutant p53-dependent cell
death. Moreover, because of a pivotal role of MDM2 in
restraining p53, blocking the MDM2–p53 interaction
to reactivate p53 function is a promising approach for
cancer therapy in patients with wild-type p53. Recently,
potent and selective small-molecule MDM2 inhibitors
have been identified, but the cancer-therapeutic ef-
fects of these MDM2 inhibitors remain to be studied.
Tumor necrosis factor-related apoptosis-inducing li-
gand (TRAIL) was also demonstrated to induce apo-
ptosis in cancerous cells, but not normal cells, from
human endometrium, ovary, cervix or Fallopian tube.
Therefore, TRAIL may be an effective treatment for
endometrial cancer and other female reproductive can-
cers, with minimal secondary effects on healthy tissue.14
Future Prospects
Female genital tract sarcomas are frequently associated
with highly aggressive behavior and poor prognosis.
Since the expression of apoptosis-related markers were
found by Liu et al to be deregulated in these sarco-
mas,12 further studies are required to explore the genetic
mutations of apoptosis-related markers in these tumors
and the upstream and downstream pathways. In this
way, the mechanisms underlying the highly malignant
nature of female genital tract sarcomas may be unrav-
eled, thereby facilitating the design of targeted therapy
that may improve the therapeutic effect of radiotherapy
and chemotherapy.
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